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Perinatal depression is common, with a prevalence 
of 10 - 15% in economically developed countries. 
These prevalence rates are even higher in low- and 
middle-income countries.[1] In South Africa (SA), the 
prevalence of perinatal depression has been estimated 
to be as high as 39% in peri-urban areas[2] and 49% in rural areas.[3] 
It is not surprising that the World Health Organization has identified 
maternal mental health as an integral component of its global 
maternal health improvement plan.[4] 
Maternal mental health within the perinatal context presents unique 
challenges for the detection and management of depressive disorders, 
especially in resource-poor countries. Diagnosis is often obscured 
by the fact that the core symptoms of depression such as fatigue, 
poor sleep, weight change and concentration difficulties are also 
effects of pregnancy and often go unnoticed. Cognitive behavioural 
therapy and interpersonal therapy are both well-established treatment 
modalities for mild to moderate perinatal depression.[5] In developing 
countries, barriers to psychotherapeutic interventions as optimal 
treatment choice include the limited availability of trained therapists, 
time constraints, child care issues, costs and the sensitivity of the 
therapist to cultural and sociodemographic factors.[6] 
Selective serotonin reuptake inhibitor (SSRI) antidepressants are 
considered the primary treatment for moderate to severe depression 
during pregnancy. Although providing antidepressant treatment 
would seem to be an obvious clinical option, extant data regarding 
the safety of its use during pregnancy remains controversial and 
conflicting. Decisions regarding the prescription of antidepressant 
treatment are often fraught with concern about potential harmful 
medication effects on the pregnancy, fetus and infant. Potential 
exposure risks associated with antidepressant drugs during pregnancy 
include the risk of teratogenicity, neonatal toxicity and the risk of 
long-term neurobehavioural sequelae. A possible reason for the 
dissonance between the evidence supporting and the practice of 
prescribing SSRI antidepressants may relate to these concerns. 
Information on potential risks remains extremely varied and 
inconsistent across sources.[7-10] This lack of clarity regarding drug 
safety creates significant uncertainty not only for treating physicians, 
but also for women seeking information about depression during 
pregnancy. It can be challenging to encourage adherence in the best 
of circumstances, even more so when suggesting medication to a 
pregnant woman who has been labelled a ‘dangerous’ patient.
When pharmacological treatment with SSRIs is indicated during 
pregnancy, the possible negative effects of untreated psychiatric 
symptoms on mother, child and family need to be carefully weighed 
against the possible adverse effects of medication use. 
This review aims to summarise and evaluate the current evidence 
base and to aid clinicians in performing a risk/benefit analysis for 
SSRI use during pregnancy and lactation.
The impact of perinatal depression 
Undetected and untreated depression can lead to detrimental effects 
for both mother and baby. These risks may be conceptualised as 
maternal, gestational, neurodevelopmental and behavioural effects. 
Maternal health
Common negative effects of maternal depression include decreased 
support from the family and social support network, poor antenatal care 
attendance, decreased ability for self-care and poor nutrition and weight 
SSRI use in pregnancy: Evaluating the risks and benefits
E du Toit,1 MB ChB, MMed (Psych), FCPsych (SA); E Thomas,2 MB ChB, Dip HIV Mx; L Koen,2 MB ChB, MMed (Psych), PhD (Psych); 
B Vythilingum,3 MB ChB, MMed (Psych), DCH, FCPsych (SA); S Grobler,4 MB ChB, MD (Psych), FCPsych (SA); N Smith,4 MB ChB, 
MMed (Psych); D Niehaus,2 MB ChB, MMed (Psych), DMed (Psych), FCPsych (SA), PhD (Psych)
1 Sophia Clinic, Panorama, Cape Town, South Africa
2 Maternal Mental Health Clinic, Stikland Hospital and Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University,
  Cape Town, South Africa
3 Department of Psychiatry, Faculty of Health Sciences, University of Cape Town, South Africa
4 Department of Psychiatry, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South Africa
Corresponding author: D Niehaus (djhn@sun.ac.za)
Selective serotonin reuptake inhibitor (SSRI) antidepressants are considered the primary pharmacological treatment for moderate to severe 
depression during pregnancy. Data regarding the safety of their use during pregnancy remain controversial and conflicting. Decisions 
regarding the prescription of antidepressant treatment are often fraught with concern around potential harmful medication effects on 
the pregnancy, fetus and infant. Information on potential risks remains extremely varied and inconsistent across sources. This lack of 
clarity regarding drug safety brings significant uncertainty not only for treating physicians, but also for women seeking information about 
depression during pregnancy. This review aims to summarise and evaluate the current evidence base and to aid clinicians in performing a 
risk/benefit analysis for SSRI use during pregnancy and lactation.
S Afr J Psychiatr 2015;22(2):48-53. DOI:10.7196/SAJP.587
May 2015  Vol. 22  No. 2    -  SAJP    49
gain.[8] Studies have shown that the interruption of antidepressant 
treatment during pregnancy results in relapse of symptoms in as many 
as 60 - 70% of women.[11] Depression during pregnancy is one of the 
strongest predictors of postpartum depression, which, in turn, has 
deleterious and long-lasting effects on infant and child wellbeing, as 
well as on the mother’s mental health.[12] The prevention of postpartum 
depression is important, as these women are more likely to have 
recurrent depressive episodes which can become chronic, leading to 
substantial impairments in the mother’s ability to care for her child. 
Suicidal tendencies associated with depression are a leading con-
tributor to maternal mortality globally. Suicidal thoughts and actual 
self-harm occur in up to 20% of mothers in low- and middle-income 
countries, in comparison with 5 - 14% of mothers in high-income 
countries.[4] Several contributing factors to suicide, such as young 
maternal age, intimate partner violence and high prevalence of perinatal 
depression, are constant reminders of why this is a serious challenge in 
the developing world. Although successful suicide following childbirth 
is rare (estimated at a rate of 0.3 per 1 000 for women referred to 
psychiatric services following childbirth), it is nonetheless a devastating 
event for the child and family involved and highlights the importance of 
effective treatment of intrapartum depressive episodes.[13] 
In SA, 60% of all first pregnancies are unplanned.[14] The first 
challenge is thus the early identification of pregnant women with 
psychiatric illness, as they are less likely to seek prenatal care than 
healthy pregnant women.[15] They are also more likely to engage in 
high-risk behaviour such as substance abuse that can be harmful to 
themselves and their unborn babies, e.g. pregnant women who abuse 
substances have higher rates of infectious diseases such as HIV.[16] 
Gestational effects
Research has suggested that maternal depression and/or anxiety 
during pregnancy is an independent risk factor for operative 
delivery,[17] preterm birth, and low birth weight.[18] Preterm delivery 
and low birth weight are the leading causes of infant mortality in both 
developed and developing countries.[19] Associations have also been 
described with serious gestational complications such as antepartum 
bleeding, pregnancy-induced hypertension, pre-eclampsia and 
decreased uterine artery blood flow.[20]
Indirect exposures associated with maternal depression, such 
as poor nutrition, poor compliance with pre- and postnatal care, 
increased use of over-the-counter remedies and substance abuse, 
increase the risk of poor obstetrical and fetal outcomes.[21] In utero 
exposure to alcohol has serious consequences for the developing 
fetus, leading to a range of conditions collectively known as fetal 
alcohol spectrum disorders (FASD).[22] Alcohol exposure affects the 
development of the brain during critical periods of differentiation 
and growth, leading to long-term cognitive and behavioural deficits. 
SA has the highest documented rate of FASD and fetal alcohol 
syndrome. A recent population-based study estimated the prevalence 
of FASD in a high-risk area of the Western Cape at between 135.1 and 
207.5/1 000.[23] 
Neurodevelopmental and behavioural effects
Increasingly psychopathologies are conceptualised as the late-stage 
culmination of aberrant developmental processes shaped by a complex 
interplay of genes and experience, including in utero experiences. 
Pregnant women with depression and/or anxiety experience greater 
life stress, and illness-related alterations in their neurobiology, with a 
potential to impact fetal neurobehavioural development via associated 
changes in the intrauterine environment.[24-26] Infants of depressed 
mothers display a number of negative behaviours such as more 
irritability, less crying, less attentiveness and fewer facial expressions 
than infants of healthy mothers.[26] 
Children of mothers with depression are at an increased risk 
of disruptive and oppositional behaviour.[27] Long-term follow-up 
studies have also shown that offspring of depressed mothers are at 
a higher risk for neuropsychiatric disorders, social impairment and 
increased risk of mortality from medical causes.[28] The STAR*D Child 
study was able to demonstrate that a remission of maternal depressive 
symptomatology, irrespective of its timing, was related to decreased 
problematic symptoms and behaviour in their offspring.[29] 
In summary, evidence suggests that untreated perinatal depression 
is not only associated with significant adverse risks for the mother, 
but also exerts a transgenerational effect on the unborn baby. The 
healthcare provider is thus advised to view maternal depression as a 
priority. Clinicians should familiarise themselves with the different 
treatment modalities available to treat depression in pregnant women 
in a safe and appropriate manner. 
Selective SSRIs: navigating the evidence base
SSRIs are one of the best-studied classes of medication used in 
pregnancy in terms of their potential risk to the newborn. Prior to 2005, 
the majority of studies supported the view that SSRIs were relatively 
safe for use in pregnancy, with no increase in the prevalence of major 
congenital malformations found.[30-32] Evidence that has since linked 
SSRI use during pregnancy with adverse birth and neonatal outcomes 
had largely been derived from retrospective cohort epidemiological 
studies and case reports.[33-35] However, correlation does not equate 
with causation. The study methodology is often flawed, failing to take 
into account a number of intrinsic confounding variables such as the 
dose, timing of exposure, and use of other medications or the severity 
of depression. SSRIs are prescribed for a number of disorders, making 
the exposed population heterogeneous and thus more difficult to 
standardise for study. Ultimately, pregnancy does not preclude illness 
or disease, and due consideration needs be given to differentiating 
between other contributing events, independent of drug effects, such 
as concurrent substance abuse, domestic violence, quality of antenatal 
care, nutrition, and comorbid medical disease. 
Impact of SSRI use during pregnancy
Several poor outcomes have been associated with maternal use of 
antidepressant treatment during pregnancy, including: gestational 
adversities, congenital anomalies, neonatal adaptation syndrome and 
neonatal persistent pulmonary hypertension. In recent years, concern 
has also arisen regarding the potential long-term effect of SSRI 
exposure in utero on neurodevelopmental outcomes.
Obstetrical complications
Some, but not all, studies suggest that the use of SSRIs during 
pregnancy increases the risk of poor obstetrical outcomes such as: 
preterm delivery, intrauterine growth restriction and the risk of 
spontaneous miscarriages.[35] In a recent meta-analysis by Huang et 
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al.[7] antidepressant use in pregnancy was significantly associated with 
low birth weight (relative risk (RR): 1.44, 95% confidence interval (CI): 
1.21 - 1.70) and preterm delivery (RR: 1.69, 95% CI: 1.52 - 1.88). The 
studies included varied widely in design, populations, control groups 
and methodology, with a high level of heterogeneity as measured by I2 
statistics for both outcomes examined. In a Danish population-based 
study, antidepressant exposure was associated with an adjusted risk 
ratio (aRR) of 1.14 (95% CI: 1.10 - 1.18) for spontaneous abortion 
compared with no exposure to antidepressants. Among women 
with a diagnosis of depression, the aRR for spontaneous abortion 
after any antidepressant exposure was 1.00 (95% CI: 0.80 - 1.24). 
Thus antidepressant use in general, as well as individual SSRI agent 
exposure, was not associated with spontaneous abortions.[36]
There have also been negative studies in this regard. Oberlander et 
al.[37] found that both the duration of gestation and the risk of preterm 
delivery did not differ significantly between depressed women who 
had used SSRIs during pregnancy and those who had not.
While some studies have shown an association between the use of 
SSRIs during pregnancy and risk of preterm delivery, and spontaneous 
miscarriage, the reviewed studies are scarce and methodologically 
inadequate to draw definitive conclusions about the hypothesised risk 
associated with exposure during early pregnancy.
Congenital anomalies
Congenital malformations may occur in the general population 
independent of any drug exposure. The majority of early studies 
were in consensus that SSRIs are unlikely to increase the 1 - 3% 
congenital abnormalities found in the general population,[38] despite 
the suggestion that SSRIs could putatively increase the incidence 
of congenital malformations as serotonin is important in aspects of 
early embryonic development that impact neural tube, brachial arch 
and heart development.[39] Although most studies have not shown an 
increase in the overall risk of major malformations,[40] some studies 
have suggested that specific SSRIs (fluoxetine (odds ratio (OR) 1.14, 
95% CI: 1.01 - 1.30) and paroxetine (OR 1.29, 95% CI: 1.11 - 1.49) are 
associated with an increased risk of major malformations.[41] Overall 
these associations have been conflicting or not replicated in other 
studies[42] and are contrary to the expectation that a teratogen would 
cause similar types of malformation across all studies.[39] 
Paroxetine’s use during pregnancy has elicited the most concern. 
During 2005, a report by the drug manufacturer of paroxetine noted 
a 1.5-fold risk of cardiac defects (primarily atrial and ventricular 
septal defects) in children exposed in utero to paroxetine v. a control 
group. This prompted the US Food and Drug Administration 
(FDA) to change the pregnancy category of paroxetine from C to 
D and issue an advisory for clinicians to consider discontinuation 
of this medication, or to reduce the dose to decrease incidence. 
The data contained in this report had not however been published 
in a peer-reviewed journal; instead they had been derived from a 
Swedish registry and a US insurance-claims database, both sources 
with inherent bias and methodological limitation.[43] Since then, 
only 1 of 5 meta-analyses investigating the risk for malformations 
associated with antidepressant use has found an increased risk of 
congenital malformation in infants exposed to paroxetine.[9] A recent, 
large Danish population-based study has provided evidence that 
may resolve this debate. Unlike previous studies, the authors were 
able to identify and include a group of depressed women who had 
avoided taking their SSRIs during pregnancy in their analysis. From 
848  786 pregnancies identified, 4 183 women were exposed to an 
SSRI during their pregnancy, and 806 ceased treatment. The risks of 
congenital malformations were similar for the SSRI-exposed group 
(adjusted OR: 2.01; 95% CI: 1.60 - 2.53), as well as for the pregnancies 
where SSRI treatment was interrupted (adjusted OR 1.85; 95% CI: 
1.07 - 3.20) (p=0.94). Additionally the risks were similar for the 
individual SSRIs, and no dose-response association was observed.[44] 
The authors concluded that previously ascribed associations between 
maternal SSRI use and cardiac malformations are likely to be due 
to ascertainment bias. Depressed women (treated or untreated) are 
more likely to have special investigations such as ultrasound and 
echocardiograms performed; therefore there is a higher likelihood of 
detection of cardiac malformations.[39]
At present it is not possible to draw definite conclusions regarding 
the teratogenicity of the different SSRIs as the available studies 
contain several methodological limitations. Evidence that SSRI 
exposure increases the risk of congenital anomalies is conflicting, but 
reassuring overall. Observed risks have been of very low magnitude 
and clinical significance remains unknown.[39,45] If there is indeed an 
increased risk, the question of biological plausibility remains.
Perinatal neonatal adaptation syndrome
A cluster of symptoms termed the perinatal neonatal adaptation 
syndrome (PNAS) has been found in up to 30% of neonates exposed to 
SSRIs late in pregnancy.[46] Other terms that have been used to describe 
this presentation include: neonatal behavioural syndrome, postnatal 
adaptative syndrome and neonatal abstinence syndrome.[47] This 
syndrome generally presents with fairly nonspecific symptoms such 
as crying, irritability, jitteriness, tremor, feeding problems, respiratory 
disturbances, muscular tone changes, impaired thermoregulation 
and, rarely, seizures. The symptoms are usually mild, transient and 
self-limiting, without a need for specific treatment. 
The impact of timing, as well as dose and duration of SSRI exposure 
is still uncertain. Initially it was suggested that late (third trimester) 
exposure to SSRIs carried a higher risk for the development of PNAS 
because SSRI withdrawal or intoxication were thought to be the 
possible underlying mechanism of PNAS. To reduce the risk of PNAS, 
or to possibly ameliorate neonatal symptoms, some researchers have 
suggested ceasing SSRI use near term. This can have deleterious 
consequences, including relapse, exacerbation of symptoms, suicidal 
ideation, especially in the vulnerable postpartum period.[48] PNAS 
has most often been reported after exposure to paroxetine, fluoxetine 
and venlafaxine.[49-51] Using population-based data linking maternal 
mental health and medication and neonatal health outcome, greater 
length of gestational exposure rather than timing of exposure was 
associated with significantly increased risk of adverse outcomes after 
controlling for maternal characterisitics.[51]
Ultimately, the mechanisms underlying this syndrome have not yet 
been fully elucidated. The pathogenesis is likely to be multifactorial, 
which would account for the variability of symptoms. Evidence 
suggests that genetic factors, such as maternal and infant hepatic 
cytochrome P450 isoenzyme genotypes are potentially involved.[47] 
Other potential contributing factors include the severity of maternal 
mental illness, prematurity, type of feeding and exposure to other 
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medication or illicit substance use.[47] General supportive measures, 
such as the provision of a quiet environment, frequent small feedings 
on demand, swaddling and increased skin-to-skin contact with the 
mother, are considered sufficient management.[49] Discontinuation, 
lowering the dose or switching to another type of antidepressant is not 
currently recommended. 
Persistent pulmonary hypertension
Persistent pulmonary hypertension of the newborn (PPHN) is a 
rare disorder occurring in approximately 1 - 2 per 1 000 births.[52] 
PPHN is a failure of the pulmonary vascular structures to reduce 
resistance at birth. This can lead to poor oxygenation, central cyanosis 
and ultimately respiratory failure. There are several established 
perinatal risk factors for the development of PPHN including 
maternal overweight, smoking, diabetes, or use of non-steroidal anti-
inflammatory drugs during pregnancy.[52] More recently, the mode of 
delivery, specifically caesarean delivery, was added to the list of risk 
factors.[53] 
Studies on the association between SSRIs and PPHN have yielded 
largely differing and conflicting results. While some studies have 
suggested an increased risk with later gestational exposure,[37,54] 
others have not.[52] As mentioned, several factors are associated with 
the development of PPHN. In a large Nordic population cohort 
study of 1 618 255 infants, the authors suggest that maternal use of 
SSRIs in late pregnancy increased the risk of persistent pulmonary 
hypotension (PPH) more than two-fold (OR 2.1; 95% CI: 1.5 - 3).[55] 
However, several other causative explanations such as the severity of 
depression, smoking, mode of delivery and maternal weight had not 
been addressed adequately. Additionally, solely using drug registry 
data carries the risk of exposure misclassification, given that it is 
not clear whether women who were issued prescriptions later in 
pregnancy took them as prescribed. Overall the observed associations 
with SSRI use have been of very low magnitude (absolute risk of 
PPHN <1%) and the clinical significance of study results remains 
unknown.[39] No study to date has described a neonatal death from 
PPHN associated with SSRI exposure. 
Despite this uncertainty of association between SSRIs and PPHN, 
both the obstetrician and the paediatrician need to be informed of 
maternal use of SSRIs to assure adequate monitoring of the newborn. 
Neurodevelopmental and behavioural outcomes
There have been few neurodevelopmental studies to date. Although 
the majority of studies have not demonstrated neurodevelopmental 
sequelae in children prenatally exposed to SSRIs, there are some 
studies that showed slight developmental delay, mainly in their motor 
function.[33,56] Small studies have shown that SSRI exposure in the 
third trimester may have subtle effects on motor development and 
motor control.[57] Nonetheless, it remains unclear whether findings 
that have been detected represent transient observations or are 
indicative of subsequent neurobehavioural problems that may be 
detected at a later age.
Beyond childhood, animal studies have shown that neonatal SSRI 
exposure during a developmentally sensitive stage of central nervous 
system development can suppress adult serotonergic signalling 
and elicits depressive- and anxiety-like behaviours in adulthood.[58] 
Human studies have also suggested that the use of SSRIs by pregnant 
women is associated with an elevated risk of developing autism 
spectrum disorder in their children.[59-61] In a recent large Danish 
birth registry analysis, Hviid et al.[61] did not demonstrate a significant 
association between maternal use of SSRIs during pregnancy and 
autism spectrum disorder in the offspring, as compared with other 
children (aRR 1.20, 95% CI: 0.90 - 1.61). However, in subsequent 
analysis, a significant association was observed between maternal 
SSRI use prior to conception and autism spectrum disorder. (aRR 
1.46, 95% CI: 1.17 - 1.81). The authors concluded that the effects 
of the maternal disorder or other unmeasured factors related to 
the maternal disorder (e.g. other medication use, smoking, parity) 
increased the risk of autism spectrum disorders, rather than the use 
of SSRIs themselves.[61]
A prospective cohort study by Nulman et al.[62] found that factors 
such as the severity of maternal depression during pregnancy, 
rather than antidepressant exposure, were better predictors of the 
child’s intellect and behaviour. Using measures such as the Conner’s 
Parent Rating Scale and Child Behaviour Checklist, it was shown 
that children born of depressed mothers exhibited clinically more 
problematic behaviours and higher temperament scores than the 
children of non-depressed women. This confirms similar findings 
from earlier studies that the degree of maternal illness rather than 
drug exposure may predict a child’s internalising and externalising 
behaviours.[63] 
Existing data on the long-term neurodevelopmental and behavioural 
outcomes for children exposed prenatally to SSRI are sparse. A major 
challenge remains disentangling the effects of maternal depression 
from maternal use of SSRIs on later neurodevelopment in offspring. 
Available evidence does not suggest that these drugs adversely 
affect neurodevelopment. Further long-term studies in this area are 
however needed.
Lactation
The benefits of breastfeeding are well established. Breastmilk is the 
ideal source of nutrients for a baby, and studies show that breastfed 
infants have less risk of mortality and morbidity (i.e. gastrointestinal 
and respiratory infections, urinary infections, sepsis, meningitis, 
necrotising enterocolitis).[64]
Breastfeeding also provides health benefits for the mother, such 
as reduced risk of breast and ovarian cancer.[65,66] Furthermore, the 
intimate bodily contact between the mother-infant dyad during 
breastfeeding fosters bonding in early infancy.[67] These early life 
experiences, specifically in terms of mother-child interactions, have a 
profound impact on adult mental and physical health.[68]
Concerns about potential harm to the nursing infant are often cited 
as a reason to cease lactation. Alternatively the question arises of 
whether an effective antidepressant treatment given during pregnancy 
should be continued when the mother wants to breastfeed. Though 
no generalisations can be made regarding antidepressant drug use 
during lactation, there is a growing body of research that supports 
most agents as safe for use. 
SSRIs are the antidepressant group for which the most data exist 
for use in lactation and their use appears to be quite safe. A number 
of factors determine the amount of SSRI present in breastmilk such 
as half-life, time of peak serum concentration, dissociation constant, 
volume of distribution, molecular size, degree of ionisation, pH of 
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plasma and milk and the solubility of the drug in water and lipids.[69] 
The SSRIs reach breastmilk in different concentrations with sertraline 
showing the lowest concentration, followed by paroxetine, fluvoxamine 
and then citalopram and fluoxetine. All SSRIs have relatively long 
half-lives and there is a risk of drug accumulation, especially in the 
neonatal period when drug clearance values are significantly reduced. 
If an SSRI is considered essential and the prescriber is selecting a drug 
for use in the postnatal period for a breastfeeding mother, fluoxetine is 
best avoided. Based on current available evidence, the long elimination 
half-life can cause the drug to accumulate in the newborn and increase 
the risk of side-effects.[49] 
Postpartum use of SSRIs is not contraindicated during breast-
feeding, and women who choose to breastfeed should be supported. 
The discontinuation of essential antidepressant treatment during the 
postpartum period should be avoided, as well as switching to another 
antidepressant. A practical recommendation is for the mother to 
consume medication immediately following breastfeeding as this 
will not only minimise the amount present in the breastmilk but also 
maximise the clearance prior to the next feed.[70]
Recommendations
An integrated, collaborative approach during the perinatal period 
presupposes thoughtful consideration of both the risks and benefits 
of treatment v. untreated disease. No medication is 100% safe during 
pregnancy and all pregnancies have risks. Unfortunately, there is no 
‘one-size-fits-all strategy’; the attainment of optimal mother-fetal 
wellbeing is more likely through individualised treatment planning. 
Given the inconclusive evidence regarding the overall safety 
of SSRI use, it is pertinent that clinicians consider both the risk 
of exposure to untreated illness, as well as antidepressant use. 
The different treatment options should be carefully evaluated 
and, if possible, non-pharmacological treatment should be offered. 
Psychotherapy should be considered a first-line treatment for mild 
or moderate depression. 
By screening and treating perinatal depression the treating 
clinician is also uniquely poised to detect additional factors which 
may put the mother and child at risk, such as intimate partner 
violence.[71] Non-pharmacological aspects of treatment should also 
include nutrition, weight management, prenatal care, childbirth 
education, and treatment for substance abuse.
Non-pharmacological interventions might not relieve moderate 
to severe depression or be available to all women. When SSRI-
prescription is contemplated, several factors influence the choice 
of antidepressant, including prior response, gestation, intention to 
breastfeed and the safety profile based on the available evidence 
and experience. There is no single best SSRI for all pregnant 
women. Current recommendations include using the lowest effective 
dose, monotherapy to avoid compounding the risk of harm, and 
avoiding changes in treatment regimens. Clinicians may be tempted 
to underdose medications in the belief that this will lessen the 
exposure risk. This however exposes the fetus to not only the negative 
effects of undertreated maternal MDD but also continued exposure to 
the medication. Rational, collaborative treatment decisions, informed 
consent, and good documentation are important when treating these 
women if SSRIs are used throughout the pregnancy. Furthermore, the 
newborn may require additional observation for the first few days 
following delivery to monitor for potential withdrawal syndromes or 
pulmonary hypertension. Liaison with the paediatrician/neonatologist 
is strongly advised.
Conclusion
Antidepressant drugs have been the most studied drugs during 
pregnancy. Although many reviews have been published 
on pregnancy outcome after maternal use of antidepressants, 
interpretation of the various results is often difficult. Whether the 
risks identified relate to SSRI treatment or perinatal depression 
and its correlates remains inconclusive. Adequate treatment of 
depression in pregnant women is however important for maternal, 
fetal and neonatal wellbeing. Moderate to more severe depression 
often requires treatment with an antidepressant, typically an SSRI. 
There is a definite and urgent need for larger, well-designed 
epidemiological studies, especially comprehensive meta-analyses 
that are sufficiently powerful to detect differences in outcomes 
for infants exposed to SSRIs in utero. Management of maternal 
depression or anxiety is best evaluated and adjusted prior to 
conception to ensure proper treatment during pregnancy. Clinicians 
should familiarise themselves with the concerns regarding potential 
adverse outcomes, critically appraise published results and use any 
medications with the necessary caution. 
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